Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

9.060 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.060
Bid (Size) 8.940 (5)
Ask (Size) 9.030 (5)
Prev. Close 9.060
Today's Range 9.060 - 9.060
52wk Range 4.070 - 12.43
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. 
Via Benzinga
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
+52.53%
+52.53%
1 Month
+10.09%
+10.09%
3 Month
-7.55%
-7.55%
6 Month
-8.58%
-8.58%
1 Year
+84.52%
+84.52%

More News

Read More
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Aurinia Pharmaceuticals Stock Is Slumping Today
Via The Motley Fool
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra'
Via Benzinga
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
Via The Motley Fool
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
Via Benzinga
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
Via Investor's Business Daily
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
Via Benzinga
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.